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Abstract
Background: Gastrojejunostomy (GJJ) is the most commonly used palliative treatment modality
for malignant gastric outlet obstruction. Recently, stent placement has been introduced as an
alternative treatment. We reviewed the available literature on stent placement and GJJ for gastric
outlet obstruction, with regard to medical effects and costs.
Methods: A systematic review of the literature was performed by searching PubMed for the
period January 1996 and January 2006. A total of 44 publications on GJJ and stents was identified
and reported results on medical effects and costs were pooled and evaluated. Results from
randomized and comparative studies were used for calculating odds ratios (OR) to compare
differences between the two treatment modalities.
Results: In 2 randomized trials, stent placement was compared with GJJ (with 27 and 18 patients
in each trial). In 6 comparative studies, stent placement was compared with GJJ. Thirty-six series
evaluated either stent placement or GJJ. A total of 1046 patients received a duodenal stent and 297
patients underwent GJJ. No differences between stent placement and gastrojejunostomy were
found in technical success (96% vs. 100%), early and late major complications 7% vs. 6% and 18%
vs. 17%, respectively) and persisting symptoms (8% vs. 9%). Initial clinical success was higher after
stent placement (89% vs. 72%). Minor complications were less frequently seen after stent
placement in the patient series (9% vs. 33%), however the pooled analysis showed no differences
(OR: 0.75, p = 0.8). Recurrent obstructive symptoms were more common after stent placement
(18% vs. 1%). Hospital stay was prolonged after GJJ compared to stent placement (13 days vs. 7
days). The mean survival was 105 days after stent placement and 164 days after GJJ.
Conclusion: These results suggest that stent placement may be associated with more favorable
results in patients with a relatively short life expectancy, while GJJ is preferable in patients with a
more prolonged prognosis. The paucity of evidence from large randomized trials may however
have influenced the results and therefore a trial of sufficient size is needed to determine which
palliative treatment modality is optimal in (sub)groups of patients with malignant gastric outlet
obstruction.
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Background
Gastric Outlet Obstruction (GOO) is a common symp-
tom in patients with cancer of the distal stomach, duode-
num and pancreas. The incidence of pancreatic cancer is
7.1 per 100,000 people of which approximately 15–20%
patients will develop GOO [1-4]. Other causes are periam-
pullary carcinoma, lymphoma and metastases to the duo-
denum or proximal jejunum [1,3-5]. Clinical symptoms
of GOO include vomiting, nausea, malnutrition and
dehydration. Most patients with GOO are therefore in a
poor clinical condition at presentation and have a short
life expectancy if left untreated [3,6,7].
Traditionally, open gastrojejunostomy (GJJ) has been the
standard palliative treatment in these patients. Open GJJ
is associated with a good functional outcome and relieves
symptoms in almost all patients. Nevertheless, early
major complications and mortality have been reported to
be substantial [3,8,9]. Most patients have delayed gastric
emptying, which is defined as the inability to tolerate flu-
ids for 8 days or more after treatment, which often causes
a prolonged hospital stay [10]. In recent years, laparo-
scopic GJJ has been introduced as an alternative to open
GJJ to relieve symptoms of malignant GOO. Laparoscopic
GJJ has been reported to be less invasive and to be associ-
ated with a faster recovery compared to open GJJ, however
mortality and morbidity of the procedure remain high
[3,6,11,12].
Palliative stent placement for GOO was first reported in
the early 1990s [13]. Stents have already extensively been
used at other sites of the gastrointestinal tract, for example
for palliation of dysphagia from esophageal cancer
[14,15]. Stent placement for GOO has been suggested to
be less invasive with a faster relief of symptoms compared
to open or laparoscopic GJJ. As a consequence, hospital
stay should be shorter in the majority of patients with
many of them being able to eat soft solids after 1–4 days.
Technical and clinical success rates have been reported to
be high and mortality related to the procedure is rare after
stent placement [16]. A disadvantage of stent placement is
however the high rate of late major complications caused
by stent migration and occlusion [1,3].
Limited data are currently available comparing stent
placement and GJJ. In this study, we reviewed the availa-
ble literature on stent placement and GJJ with respect to
technical and clinical success, complications, hospital
stay, survival and procedure-related costs.
Methods
A systematic review of the published literature was per-
formed by searching PubMed for the period January 1996
until December 2005, combining the following search
terms: gastric outlet obstruction, duodenum, stent, gastro-
jejunostomy, surgical bypass and gastroenterostomy. A
total of 166 studies were found using these search terms,
of which 58 studies reported results on technical success,
clinical success, complications, hospital stay, survival and
costs for both treatment modalities. Fourteen publica-
tions were excluded for one or more of the following cri-
teria: single case reports, abstracts, one of these treatments
used in combination with a curative treatment modality
or use of the same data in more than 1 article. In total, 44
studies were included (Table 1).
Definitions
For this review, we used the following definitions:
- Technical success: Adequate positioning and deploy-
ment of the stent or technical feasibility to perform a GJJ.
- Clinical success: Relief of symptoms and/or improve-
ment of oral intake.
- Major complications: Life-threatening or severe compli-
cations such as perforation, stent migration, hemorrhage,
fever, jaundice or severe pain, often requiring additional
treatment and hospitalization. Major complications were
divided in early (≤ 7 days after treatment) or late (>7 days
after treatment) complications.
- Minor complications: Complications which were not
life-threatening or moderately severe, such as mild pain,
wound infection, mild fever or occasionally vomiting
without obstruction.
- Persistent obstruction: Persistence of obstructive symp-
toms after the intervention.
- Recurrent obstruction: Recurrent obstructive symptoms
during follow-up.
Statistics
Technical and clinical success, complications, persistent
and recurrent obstruction, hospital stay and survival rates
were pooled. Odds ratios (OR) with 95% confidence
interval (CI) were calculated for technical success, clinical
success, early and late major complications, and minor
complications using data from the randomized and com-
parative studies. Odds ratios were not calculated for a
study when the event was detected in all patients. Calcu-
lations were done with SPSS 12.0 and RevMan 4.2. A p <
0.05 was considered to be statistically significant.
Results
Study characteristics
A total of 44 studies were included in this review [1,4-
12,17-50]. Study characteristics are shown in Table 1.
Only two studies had a randomized design (with 27 andBMC Gastroenterology 2007, 7:18 http://www.biomedcentral.com/1471-230X/7/18
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Table 1: Case series included
Author Study type Years Intervention N Age Impact factor journal
Randomized studies
Mehta et al [17] Randomized Unknown LGJJ 14 68 2
Stent 13 70
Fiori et al [18] Randomized 2001–2002 OGJJ 9 70 1,4
Stent 9 72
Comparative studies
Johnsson et al [19] Prospective 1999–2004 OGJJ 15 72 2
Stent 21 78
Mittal et al [20] Retrospective 1989–2002 LGJJ 14 68 5,1
OGJJ 16 68
Stent 16 64
Del Piano et al [7] Retrospective 1997–2002 OGJJ 23 73 3,5
Stent 24 75
Maetani et al [8] Retrospective 1993–2002 OGJJ 19 69 4
Stent 20 72
Wong et al [6] Retrospective 1988–1998 OGJJ 17 ns 2
Stent 6 ns
Yim et al [21] Retrospective 1994–1999 OGJJ 15 ns 3,5
Stent 12 68
Prospective studies
Lillemoe et al [5] Prospective 1994–1998 OGJJ 44 67 5,9
Van Heek et al [10] Prospective 1998–2002 OGJJ 36 63 5,9
Jung et al [22] Prospective 1999–2000 Stent 39 63 1,7
Pinto Pabon et al [24] Prospective 2001 Stent 31 72 1
Kim et al [26] Prospective 2000–2003 Stent 29 64 4
Holt et al [27] Prospective 2000–2004 Stent 28 76 3,5
Schiefke et al [28] Prospective 1999–2001 Stent 20 ns 3,5
Jung et al [23] Prospective 1998–1999 Stent 19 65 5,1
Jeong et al [29] Prospective 1999–2000 Stent 18 56 2,4
Lopera et al [30] Prospective 2000–2001 Stent 16 58 1,7
Profili et al [31] Prospective 1994–2000 Stent 15 65 1,2
Lee et al [32] Prospective 1997–2000 Stent 11 68 1
Baere et al [33] Prospective 1997 Stent 10 54 0,8
Bethge et al [34] Prospective 1997 Stent 6 68 4,7
Espinel et al [1] Prospective 1999–2000 Stent 6 76 1,4
Retrospective studies
Brune et al [12] Retrospective 1993–1995 LGJJ 16 67 2
Choi et al [35] Retrospective 1999–2000 LGJJ 10 59 2
Bergamaschi et al [36] Retrospective 1991–1996 LGJJ 9 ns 1,2
Alam et al [37] Retrospective 1998–2000 LGJJ 8 67 2
Bergamaschi et al [36] Retrospective 1991–1996 OGJJ 22 ns 1,2
Choi et al [35] Retrospective 1998–2000 OGJJ 10 60 2
Telford et al [38] Retrospective 1996–2003 Stent 176 65 3,5
Song et al [39] Retrospective 2001–2004 Stent 102 58 1,7
Bessoud et al [11] Retrospective Unknown Stent 72 62 1,7
Nassif et al [40] Retrospective 1998–2001 Stent 63 73 4
Kim et al [26] Retrospective 1995–1999 Stent 49 57 0,2
Adler et al [4] Retrospective 1998–2001 Stent 36 61 4,7
Kaw et al [41] Retrospective 1998–2001 Stent 33 62 2
Razzaq et al [9] Retrospective 1996–2000 Stent 28 69 0,9
Park et al [42] Retrospective 1996–1999 Stent 24 43 5,1
Aviv et al [43] Retrospective 1998–1999 Stent 15 61 1,5
Feretis et al [44] Retrospective 1993–1994 Stent 12 64 4
Soetikno et al [46] Retrospective 1995–1997 Stent 12 60 3,5
Yates et al [47] Retrospective 1994–1996 Stent 11 71 4
Feretis et al [45] Retrospective Unknown Stent 10 72 3,5
Nevitt et al [48] Retrospective 1991–1997 Stent 8 63 2
Venu et al [49] Retrospective Unknown Stent 8 66 4
Ely et al [50] Retrospective 1998–2002 Stent 5 65 2
ns = not specified
OGJJ = Open gastrojejunostomy
LGJJ = Laparoscopic gastrojejunostomyBMC Gastroenterology 2007, 7:18 http://www.biomedcentral.com/1471-230X/7/18
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18 patients included[17,18]). Stent placement was pro-
spectively or retrospectively compared with GJJ in 6 stud-
ies [6-8,19-21]. Two retrospective studies compared
laparoscopic GJJ with open GJJ [35,36]. Thirty-four stud-
ies evaluated either stent placement or GJJ. According to
the Delphi criteria, we assessed the quality of the rand-
omized and comparative trials with regard to: a) method
of randomization, b) treatment allocation, c) similarity
between groups, d) specification of eligible criteria, e)
blinded outcome of assessor, care provider and patient, f)
information on primary outcome, g) and intention-to-
treat analysis [51]. Applying these criteria made clear that
the quality of the trials was limited.
Patient characteristics
A total of 1046 patients received a duodenal stent (mean
age: 64 years) and 297 patients underwent GJJ (mean age:
67 years).
Biliary drainage some time before stent placement was
performed in 76/579 (13%) patients, during stent place-
ment in 34/579 (6%), and after stent placement in 31/
579 (5%) [1,4,8,11,17,19,20,30,38-40,43,46]. A biliary
drainage procedure some time before GJJ was performed
in 18/102 (18%) patients, during GJJ in 16/102 (16%)
and after GJJ in 17/102 (17%) [8,12,17,19,20,20,37].
Results on study outcomes are shown in Table 2.
Technical success
Stent placement was usually performed by endoscopy in
combination with fluoroscopy. The stents that were used
included enteral Wallstents and Niti-S stents, esophageal
Memotherm stents, Ultraflex stents, Choo stents, Gian-
turco-Z stents, Song stent, Flamingo Wallstents and Endo-
coil stents. The surgical technique that was used for the GJJ
included an open or laparoscopic procedure that was per-
formed in an antecolic or retrocolic way.
Stent placement was technically feasible in 972/1012
(96%) patients and GJJ in 203/204 (99%) patients (Table
3). The main reasons for technical failure of stent place-
ment were dislocation of the stent during the procedure,
no passage of the guidewire through the stricture, failure
to deploy or release the stent from the delivery system.
The reason for technical failure to perform a GJJ was the
finding of peritoneal carcinomatosis during the proce-
dure.
Clinical success
Clinical success was 89% (890/1000 patients) after stent
placement and 72% (79/110) after GJJ (Table 3). Infor-
mation on food intake was available in most studies eval-
uating stent placement and in only one study that had
included a small number of patients receiving a GJJ [19].
Based on the available data, we scored the results on food
intake using the standardized Gastric Outlet Obstruction
Scoring System (GOOSS) score, with 0 = no oral intake, 1
= liquids only, 2 = soft foods and 3 = solid food/full diet
[4]. Food intake before the intervention was poor with no
difference between patients undergoing stent placement
or GJJ. The mean GOOSS score was 0 in 148/238 (62%)
patients, 1 in 78/238 (33%) and 2 in 12/238 (5%). Fol-
lowing treatment with a stent or GJJ, food intake
improved in the majority of patients. After stent place-
ment, the GOOSS score was 0 in 18/306 (6%) patients, 1
in 68/306 (22%), 2 in 122/306 (40%) and 3 in 98/306
(32%). One week after GJJ, the GOOSS score was 0 in 5/
14 (36%) patients, 1 in 7/14 (50%), 2 in 1/14 (7%) and
3 in 1/14 (7%).
Complications
Early major complications were not different between
stent placement (7%; 43/609) and GJJ (4%; 6/159)(Table
3). Early major complications after stent placement were
mainly stent migration and dysfunction of the stent and
after GJJ, jaundice and bleeding. In most patients with
early major complications, a reintervention was per-
formed. In addition, no differences in late major compli-
cations between stent placement (18%; 171/950) and GJJ
(17%; 34/201) were found. The most commonly
observed late complications after stent placement were
stent migration and occlusion either by tumor in- or over-
growth or food. After GJJ, late major complications
included leakage at the anastomotic site, fever and dys-
function of the GJJ.
Minor complications occurred more frequently after GJJ
(33%; 66/201) than after stent placement (9%; 66/732).
Minor complications after stent placement included mild
pain in the upper abdominal region, vomiting or mild
bleeding, whereas after GJJ delayed gastric emptying and
wound infections were most frequently seen.
Persistent obstructive symptoms after treatment occurred
in 43/535 (8%) patients after stent placement and in 10/
106 (9%) following GJJ.
A reintervention for recurrent obstructive symptoms was
more frequently performed after stent placement than
after GJJ (18%; 147/814 vs. 1%; 1/138). Causes of recur-
rent obstruction after stent placement included stent
occlusion by tumor in- and overgrowth or food.
Hospital stay and survival
Mean hospital stay was shorter after stent placement (7
days, n = 324) than after GJJ (13 days, n = 385). Mean sur-
vival after stent placement was 105 days (n = 923) and
after GJJ 164 days (n = 246).B
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Table 2: Results on technical and clinical success, hospital stay, complications, survival and 30-day mortality
Author Intervention N Technical success  Clinical success  Hospital stay  Major complications  Minor complications  Survival  30-day mortality 
(%) (%) (days) Early (%)  Late (%) (%) (days) (%)
Randomized studies
Mehta et al LGJJ 14 93 ns 11 0 0 62 ns 23
Stent 13 77 ns 5 0 0 0 ns 20
Fiori et al OGJJ 9 100 89 10 11 0 11 ns ns
Stent 9 100 100 3,1 11 0 11 ns ns
Comparative studies
Johnsson et al OGJJ 15 100 81 15 0 13 ns 99 27
S t e n t 2 1 1 0 0 1 0 0 7 5 1 457 6 2 9
Mittal et al LGJJ 14 ns ns 7 0 36 7 119 ns
OGJJ 16 ns ns 10 0 31 ns 120 ns
Stent 16 ns ns 2 0 0 0 56 ns
Del Piano et al OGJJ 23 100 56 24 0 30 61 70 30
Stent 24 96 92 3 0 17 ns 96 0
Maetani et al OGJJ 19 100 84 30 26 0 5 79 16
Stent 20 100 80 15 5 25 10 55 25
Wong et al OGJJ 17 ns ns 15 ns ns ns 64 18
Stent 6 ns ns 4 ns ns ns 98 0
Yim et al OGJJ 15 ns ns 14 ns ns ns 92 ns
Stent 12 94 81 4 8 17 ns 94 ns
Prospective studies
Lillemoe et al OGJJ 44 100 ns 8,5 0 0 32 249 0
Van Heek et al OGJJ 36 100 ns 11 0 21 25 216 3
Jung et al Stent 39 97 95 ns 8 28 3 134 10
Pinto Pabon et al Stent 31 100 90 ns 0 10 29 92 29
Kim et al Stent 29 90 96 18 0 29 ns 124 0
Holt et al Stent 28 93 93 7 0 21 ns 51 42
Schiefke et al Stent 20 100 100 ns ns ns ns 144 ns
Jung et al Stent 19 95 100 ns 26 0 ns ns 0B
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Jeong et al Stent 18 100 94 ns 6 22 11 85 ns
Lopera et al Stent 16 94 81 ns 19 0 13 84 ns
Profili et al Stent 15 100 93 ns 0 14 14 ns 0
Lee et al Stent 11 87 82 ns 0 0 64 ns ns
Baere de et al Stent 10 100 80 2 10 10 20 93 ns
Bethge et al Stent 6 100 100 ns 0 33 0 23 83
Espinel et al Stent 6 100 100 2,5 0 0 ns 98 0
Retrospective studies
Brune et al LGJJ 16 100 81 7 6 0 19 87 0
Choi et al LGJJ 10 100 100 9 0 0 30 ns ns
Bergamaschi et al LGJJ 9 10 ns ns ns 348 ns
Alam et al LGJJ 8 100 88 7 13 75 ns ns ns
Bergamaschi et al OGJJ 22 15 ns ns 294 ns ns
Choi et al OGJJ 10 100 100 13 0 10 70 ns ns
Telford et al Stent 17
6
97 84 ns ns 9 6 97 ns
Song et al Stent 10
2
99 84 ns ns 9 2 92 2
Bessoud et al Stent 72 97 90 ns 1 14 1 120 ns
Nassif et al Stent 63 95 92 6 33 67 ns 210 ns
Kim et al Stent 49 100 92 7 17 10 70 18 ns
Adler et al Stent 36 100 97 ns 3 3 22 83 ns
Kaw et al Stent 33 97 88 ns 0 13 12 102 ns
Razzaq et al Stent 28 96 91 ns ns 27 4 95 18
Park Stent 24 75 67 ns 4 38 ns 129 0
Aviv et al Stent 15 93 93 ns 13 20 ns 72 ns
Feretis et al Stent 12 100 92 ns 8 0 0 ns 0
Soetikno et al Stent 12 100 75 2 ns ns 25 ns ns
Yates Stent 11 91 91 ns ns ns 63 77 ns
Feretis et al Stent 10 100 100 ns 0 20 ns ns ns
Nevitt et al Stent 8 100 88 ns 0 38 ns 141 0
Venu et al Stent 8 100 100 ns 0 10 0 ns 13
Ely et al Stent 5 100 100 ns 0 0 20 ns ns
ns = not specified
OGJJ = Open gastrojejunostomy
LGJJ = Laparoscopic gastrojejunostomy
Table 2: Results on technical and clinical success, hospital stay, complications, survival and 30-day mortality (Continued)BMC Gastroenterology 2007, 7:18 http://www.biomedcentral.com/1471-230X/7/18
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Costs
Total costs of stent placement and GJJ were compared in
three non-randomized studies [19-21]. In the study by
Yim et al [21], mean total costs were $9,921 for stent
placement and $28,173 for OGJJ. Only procedural costs
were used in this calculation. In the study by Mittal et al
[20], information was collected on procedural and post
procedural costs. Mean costs were $8,680 for stent place-
ment, $20,060 for OGJJ and $16,552 for LGJJ. Johnsson
et al [19] included procedural costs, postoperative care,
hospital stay and additional procedures. Mean costs were
$8,163 for stent placement and $10,224 for OGJJ.
Odds ratios for available comparative and randomized 
studies
Odds ratios were analyzed for technical success, clinical
success, early major complications, late major complica-
tions and minor complications using the two randomized
studies [17,18] and 6 comparative studies [6-8,19-21].
The results showed no difference in technical success rate
between stent placement and GJJ (OR: 0.22, CI: 0.02–2.1,
p = 0.2). The clinical success rate seemed however higher
after stent placement than after GJJ (OR: 3.39, CI: 0.8–
14.3, p = 0.1). The results for early major and late major
complications showed no clear differences between stent
placement and GJJ (OR: 0.49, CI: 0.1–2.6, p = 0.4 and OR:
0.74, CI: 0.1–4.0, p = 0.7, respectively). Finally, no differ-
ences in minor complications between the two treatment
modalities were found (OR: 0.75, CI: 0.1–5.0, p = 0.8).
Discussion
This review summarizes the published results on duode-
nal stent placement and GJJ as palliative treatment modal-
ities for GOO. There is a paucity of evidence to conclude
that either one of these two treatment modalities gave bet-
ter treatment results. The results of this review suggest
however that patients with a duodenal stent have a shorter
hospital stay, a more frequent and faster relief of obstruc-
tive symptoms, which may be associated with fewer
minor complications than those treated with a GJJ. Never-
theless, patients after a GJJ have fewer recurrences of
obstructive symptoms and therefore the need for reinter-
ventions is lower in GJJ patients than in those being
treated with a stent.
The main objective of a palliative procedure in patients
with malignant GOO is to restore the ability to eat. This
review demonstrates that clinical success, defined as
improvement of food intake and/or relief of symptoms,
was more common after stent placement than after GJJ,
with the OR also showing better, but statistically not sig-
nificant, results after stent placement than after GJJ (OR =
3.39, CI: 0.8–14.3, p = 0.1). As stent placement is a less
invasive treatment than GJJ, this may well explain why a
faster relief of symptoms is seen with this treatment
modality. In addition, the position of the anastomosis at
the greater curvature after a GJJ may also contribute to the
less favorable results following a surgical procedure. Nev-
ertheless, our results are only based on studies with small
patient numbers, and more and larger randomized studies
are needed.
This review showed no differences in early and late major
complications between stent placement and GJJ, which
was confirmed by the ORs obtained from the randomized
and comparative studies. Minor complications occurred
more frequently after GJJ than after stent placement if all
studies were compared. The OR however, did not indicate
a difference between stent placement and GJJ (OR: 0.75,
CI: 0.11–5.04, p = 0.77). Remarkably, complication rates
varied widely in the reviewed studies, which may have
been caused by differences in patient age, clinical condi-
tion, sample size, operator experience and in the defini-
tions used for complications in the different series and
studies that were reviewed. In addition, it was not always
possible to detect whether a complication was indeed
associated with the treatment modality or with progres-
sion of the malignant disorder.
Table 3: Summary of the main study outcomes of stent placement and gastrojejunostomy in patients with malignant gastric outlet 
obstruction
Stent GJJ
Technical success (%) 972/1012 (96) 203/204 (99)
Clinical success (%) 890/1000 (89) 79/110 (72)
Complications (%)
Early major complications 43/609 (7) 6/159 (4)
Late major complications 171/950 (18) 34/201 (17)
Minor complications 66/732 (9) 66/201 (33)
Persistent obstructive symptoms 43/535 (8) 10/106 (9)
Reintervention 147/814 (18) 1/138 (1)
Mean hospital stay (days, [range]) 7 (2–18) 13 (7–30)
Mean survival (days, [range]) 105 (23–210) 164 (64–348)BMC Gastroenterology 2007, 7:18 http://www.biomedcentral.com/1471-230X/7/18
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Recurrent obstructive symptoms, necessitating a reinter-
vention, occurred more frequently after stent placement
than after GJJ. The majority of recurrent obstructive symp-
toms after stent placement were caused by stent occlusion
from either tumor in- or overgrowth, or food obstruction.
Duodenal stent obstruction by tumor in- or overgrowth
remains a problem, especially when non-covered stents
are used. The use of covered stents in the duodenum may
however lead to a higher incidence of stent migration and
may also lead to an increased incidence of biliary obstruc-
tion and even pancreatitis due to obstruction of the com-
mon bile duct and/or pancreatic duct by the covered
device [23,25,29,30,42]. Stent migration seems to occur
in a shorter time period (range: 1–121 days) after stent
placement than recurrent obstructive symptoms caused
by tumor in- or overgrowth or food debris (range: 11–273
days). In addition, stent migration seems to occur at a
shorter time period and more frequently after placement
of a covered stent (19%) than after placement of a uncov-
ered stent (6%) [11,23,24,26,29-31,39,42,47].
Our review suggests that initial costs are lower for stent
placement than for a surgical procedure. However, in the
few studies that evaluated costs, reintervention and addi-
tional care costs were not taken into consideration [19-
21]. As GJJ was found to be associated with a prolonged
hospital stay, initial costs are likely to be higher following
GJJ. Following stent placement however, a higher inci-
dence of reinterventions for recurrent obstruction is likely
to occur and this may result in more or less similar costs
for GJJ and stent placement on the long term. A future
cost-analysis study is needed that includes all costs of
stent placement and GJJ involved in the whole period of
time that these patients survive.
A number of issues are important to consider before con-
cluding that either one of these treatment modalities is
favorable in patients with a GOO. First, only 2 rand-
omized trials and 6 comparative studies have so far been
performed including small patient numbers. The prospec-
tive and retrospective design of most studies included in
this review resulted in a minimal access to primary study
outcomes and a comparison between potentially non-
comparable patient populations. In most studies, no dif-
ferentiation was made with respect to underlying
malignancies. It is well known that survival in patients
with GOO caused by pancreatic carcinoma is shorter than
that in patients with gastric- or duodenal carcinoma [52].
Pancreatic cancer was the most common cause of GOO in
various series. However, specific results for different types
of patients were not available. Therefore survival rates
may have been over- or underestimated depending on the
type of patients that were included.
Secondly, several stent types were used in the different
studies, whereas in some studies also more than one stent
type was used. Again, specific data on outcome for indi-
vidual stent types were often not available. Moreover, in
several studies, esophageal stents rather than enteral
stents were used. This could have influenced the compli-
cation rate, as esophageal stents are often covered, in con-
trast to enteral stents, resulting in an increased risk of stent
migration [53]. Moreover, as esophageal stents, in con-
trast to enteral stents, cannot be placed through-the-
scope, placement of these devices may have been techni-
cally more demanding. Only two studies compared open
GJJ with laparoscopic GJJ. These comparative studies sug-
gested that both hospital stay and time to restore the abil-
ity to eat were shorter after laparoscopic GJJ than after
open GJJ. However additional, and preferably rand-
omized studies are needed before a recommendation in
favor of a laparoscopic procedure can be given in these
patients.
Finally, publication bias (the selective reporting of studies
with positive results) may result in overestimation of tech-
nical and clinical success rates and survival, and underes-
timation of complications and hospital stay. We assessed
publication bias and found no clear effect of sample size
or impact factor of the journal on the different endpoints
(results not shown). Using the Delphi criteria to assess the
quality of the randomized and comparative trials, made
clear that the quality of the assessed trials was limited
[51]. In addition, the quality of the patient series was low
because of small patient populations and minimal access
to primary data. A high-quality trial may alter the interpre-
tation of the benefit of the two treatment modalities. The
results of this review should not be considered as a critical
appraisal, but addresses the possible differences in treat-
ment effects between stent placement and GJJ.
Conclusion
Despite the above-mentioned limitations, it seems rea-
sonable to suggest that stent placement is associated with
more favorable short-term results, whereas GJJ may be a
better treatment option in patients with a more prolonged
survival. The results of this review suggest that a trial with
a sufficient number of patients is indicated in which
patients with malignant GOO are randomized to stent
placement or GJJ in order to define treatment guidelines
for individual patients based on the underlying disorder
and prognosis. In addition, a longer follow-up of patients
is needed to assess the different endpoints, and, if indi-
cated, to perform a cost-effectiveness analysis.
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